Celgene Has A Swift Start For Pomalyst Launch
This article was originally published in The Pink Sheet Daily
The biotech did better than Wall Street expected with its first sales figures for multiple myeloma drug Pomalyst. But it’s still very early going. Continuing to expand its hematology oncology franchise, including main revenue-driver Revlimid, remains a primary focus for Celgene.
You may also be interested in...
Biogen Idec’s Tecfidera, on track to generate more than $1 billion in sales its first 12 months on the market, was the exceptional drug launch of 2013, in a year that included few breakout stars.
A $100 million, non-dilutive investment will keep Acetylon off the market, giving Celgene the right to buy it for a minimum of $500 million up-front within a pre-determined time window. For now, Acetylon retains all rights to its pipeline, including Phase Ib multiple myeloma drug ACY-1215.
Positive opinions from Europe's top drug assessment panel in May have included a long-acting "biobetter" lipegfilgrastim from Teva, a once-weekly HGH injection from Biopartners GmbH, and a smallpox vaccine developed by Bavarian Nordic with funding from the U.S. BioShield program.